Literature DB >> 2788089

Plasma tenoxicam concentrations after single and multiple oral doses.

C Crevoisier1, P Heizmann, I Forgo, U C Dubach.   

Abstract

The pharmacokinetics of single- and multiple-dose administration of tenoxicam 20 mg were evaluated in 8 healthy males. Maximum plasma concentration (Cmax) after the first dose was 2.76 +/- 0.48 micrograms/ml (mean +/- s.d.) and the time to reach Cmax (Tmax) was 5.0 +/- 3.0 h. The area under the plasma concentration-time curve (AUC0-infinity) after a single administration of tenoxicam was 242.5 +/- 73.5 micrograms x h/ml. The elimination half-life (t1/2) was 66.3 +/- 15.8 h and the plasma concentration at 24 hours after dosing (Cmin) was 1.84 +/- 0.33 micrograms/ml. Steady-state plasma concentrations of tenoxicam were virtually reached after 10 consecutive daily doses. At steady-state, Cmax averaged 13.63 +/- 3.33 micrograms/ml and Tmax remained 5.0 +/- 3.0 hours. AUC within a dosing interval at steady-state was 262.2 +/- 67.0 micrograms x h/ml, Cminss was 9.67 +/- 3.25 micrograms/ml, and t1/2 averaged 74.2 +/- 13.3 h. The average fluctuation during multiple-dose administration was 26.8 +/- 8.0% and the accumulation ratio was 5.82 +/- 0.60. Steady-state pharmacokinetic parameters predicted from the first-dose data slightly underestimated observed values, but the results supported the assumption of linear pharmacokinetics during multiple-dose tenoxicam administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788089     DOI: 10.1007/BF03190838

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  15 in total

1.  Pharmacokinetics of ketoprofen in the elderly.

Authors:  C Advenier; A Roux; C Gobert; P Massias; O Varoquaux; B Flouvat
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

2.  Estimating the accumulation of drugs.

Authors:  W A Colburn
Journal:  J Pharm Sci       Date:  1983-07       Impact factor: 3.534

3.  The pharmacokinetics of benoxaprofen in elderly subjects.

Authors:  R C Hamdy; B Murnane; N Perera; K Woodcock; I M Koch
Journal:  Eur J Rheumatol Inflamm       Date:  1982

4.  Pharmacokinetic studies of benoxaprofen in geriatric patients.

Authors:  A Kamal; I M Koch
Journal:  Eur J Rheumatol Inflamm       Date:  1982

5.  Determination of tenoxicam, and the isolation, identification and determination of Ro 17-6661, its major metabolite, in human urine.

Authors:  D Dell; R Joly; W Meister; W Arnold; C Partos; B Guldimann
Journal:  J Chromatogr       Date:  1984-12-28

6.  Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly.

Authors:  H A Bird; R J Francis; P Le Gallez; J Hill; J S Dixon; J G Allen; V Wright
Journal:  Eur J Rheumatol Inflamm       Date:  1985

7.  Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam.

Authors:  C J Richardson; K L Blocka; S G Ross; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Pharmacokinetics of azapropazone in the elderly.

Authors:  A E Ritch; W N Perera; C J Jones
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

9.  Determination of tenoxicam in human plasma by high-performance liquid chromatography.

Authors:  P Heizmann; J Körner; K Zinapold
Journal:  J Chromatogr       Date:  1986-01-10

10.  Pharmacokinetics of tenoxicam in patients with impaired renal function.

Authors:  F F Horber; T W Guentert; E Weidekamm; P Heizmann; C Descoeudres; F J Frey
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more
  4 in total

Review 1.  Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic diseases.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

2.  Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients.

Authors:  Ingolf Meineke; Dietrich Türck
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

Review 3.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of tenoxicam.

Authors:  O G Nilsen
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.